The forum, hosted by Jubilant Biosys, prioritized the mechanics of modern drug development, specifically addressing the persistent gap between scientific innovation and capital access. With four startups presenting their platforms during the Emerging NewCos Showcase, the event moved beyond theoretical discussion to facilitate direct investment pitches. Attendees scrutinized the shifting landscape of biopharma, where success hinges on the strategic alignment of research partners and financial backers.
Jubilant Biosys Convenes Industry Leaders at 2nd EDGE Innovation Forum
In the heart of San Diego’s biotech corridor, over 30 C-suite executives and representatives from 50 organizations gathered on July 23 for the second EDGE Innovation Forum. The event served as a high-stakes bridge between emerging drug discovery startups and the venture capital firms necessary to fuel their therapeutic pipelines.
TJ Sigler, Senior Vice President of Business Development at Jubilant Biosys, noted that while the broader funding climate shows signs of recovery, many discovery programs remain stalled. The forum aimed to dismantle these barriers by connecting founders with key decision-makers from firms like Red Tree Venture Labs and LYZZ Capital. By blending expert panel discussions with curated networking, the organizers sought to accelerate the timeline for bringing next-generation therapies to clinical realization.
Comments (0)
No comments yet. Be the first!